Search Results - recombinant

15 Results Sort By:
Rabies Vaccine for the Oral Immunization of Domesticated Animals, Wildlife and Feral Animals
This invention, developed by the CDC and collaborators, entails a live, attenuated recombinant rabies virus vaccine that can elicit an effective anti-rabies immune response in animal recipients. Inoculation with a live, attenuated, rabies virus allows for the optimized production of immunity in the absence of pathogenicity. Oral administration of...
Published: 10/28/2024   |   Inventor(s): Charles Rupprecht
Keywords(s): CDC Docket Import, CDC Docket Import NP, DC5BXX, DC5XXX, DCXXXX, Dogs, DXXXXX, ENGINEERED, GENETICALLY, Immunization, rabies, recombinant, Stray, Vaccine, VLXXXX, VOXXXX, WFXXXX, Wildlife, WJXXXX, WMXXXX, XEXXXX, YBXXXX, YCXXXX
Category(s): Collaboration Sought > Collaboration, TherapeuticArea > Infectious Disease, Application > Occupational Safety and Health, Application > Therapeutics, Application > Vaccines, Application > Consumer Products
Novel One-Well Limiting-Antigen Avidity Enzyme Immunoassay to Detect Recent HIV-1 Infection Using a Multi-subtype Recombinant Protein
This CDC developed Limiting-Antigen avidity Enzyme Immunoassay (LAg-avidity-EIA) provides an easy way to measure increasing binding strength (avidity) of HIV antibodies as part of maturation HIV antibodies after seroconversion, providing a method to distinguish early-stage from long-term HIV-1 infection. Surveillance of HIV-1 provides information on...
Published: 10/28/2024   |   Inventor(s): Bharat Parekh
Keywords(s): AA5XXX, AAXXXX, Avidity, Avidity-EIA, AXXXXX, CDC Docket Import, CDC Docket Import CDC Prosecuting, CGH-DGHA, DA4AXX, DA4XXX, DAXXXX, DDXXXX, Detect, Development, DXXXXX, Enzyme, HIV, IMMUNOASSAY, Infection, Inmunoassay, LAg, Limiting-antigen, Listed LPM Houze as of 4/15/2015, Multi-subtype, NCHHSTP, One-well, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, Protein, RECENT, recombinant, RIDR-M, VLXXXX, WBXXXX, WFXXXX, WIXXXX, XAXXXX, XCXXXX, XEXXXX, YBXXXX
Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, TherapeuticArea > Infectious Disease, Application > Consumer Products, TherapeuticArea > Immunology, Application > Diagnostics, ResearchProducts > Antibodies, Application > Therapeutics, Application > Occupational Safety and Health, Application > Research Materials
Novel Rift Valley Fever Virus Vaccines
This invention relates to recombinant Rift Valley fever (RVF) viruses containing deletions in one or more virulence genes. The recombinant RVF viruses, generated using a plasmid-based reverse genetics system, can be used as vaccines to prevent RVF infection in livestock and humans. The recombinant RVF viruses grow to high titers, provide protective...
Published: 10/28/2024   |   Inventor(s): Cesar Albarino, Stuart Nichol, Thomas Ksiazek, Brian Bird
Keywords(s): Biodefense, bioterrorism, Bioterrorist, CDC Docket Import, CDC Docket Import CDC Prosecuting, DB4BXX, DB4XXX, DC1XXX, DC5BXX, DC5XXX, DCXXXX, DEVELOPING, DXXXXX, FEVER, Livestock, Method, methodology, Methods, Mosquito, Mosquitoes, OID-NCEZID-DHCPP, recombinant, Recombinant DNA, RIFT, rift valley, rift valley fever, rift valley fever virus, RVF, travel, traveler, travelers, tropical, Vaccine, Valley, VBXXXX, Vector, Vector-based, Vector-borne, Vector-borne diseases, VETERINARY, VETERINARY vaccine, viral, virus, Viruses, VLXXXX, VOXXXX, WAXXXX, WIXXXX, WMXXXX, XEXXXX, XHXXXX, YBXXXX, YCXXXX, Zoo, Zoonotic
Category(s): Collaboration Sought > Licensing, TherapeuticArea > Infectious Disease, Application > Therapeutics, Application > Vaccines, Application > Consumer Products, Application > Diagnostics, ResearchProducts > Research Equipment, Application > Research Materials
Recombinant NIE Antigen from Strongyloides stercoralis
Strongyloides stercoralis is an intestinal nematode endemic that affects an estimated 30 to 100 million people worldwide. Many of these individuals may be asymptomatic for decades. The present invention discloses a NIE recombinant antigen that can be used in improved assays and diagnostics for S. stercoralis infection. The NIE antigen is the only...
Published: 10/28/2024   |   Inventor(s): Ravi Varatharajalu, Franklin Neva, Thomas Nutman
Keywords(s): ANTIGEN, DA2XXX, DAXXXX, DDXXXX, DXXXXX, recombinant, S., SS-NIE, Stercoralis
Category(s): Collaboration Sought > Licensing, Application > Research Materials, Application > Diagnostics, TherapeuticArea > Infectious Disease
Novel Recombinant Rabies Vaccine Also Capable of Immunocontraception
This invention relates to a recombinant, attenuated rabies vaccine that is also capable of inhibiting reproductive fertility. An Evelyn-Rokitnicki-Abelseth (ERA) rabies vaccine backbone, combined with a reproductive-specific protein, such as gonadotropin-releasing hormone (GnRH) or the sperm-binding zona-pellucida-glycoprotein-3 (ZP3) receptor, allows...
Published: 10/28/2024   |   Inventor(s): Charles Rupprecht, Xianfu Wu
Keywords(s): AFXXXX, Agents, AXXXXX, CDC Docket Import, CDC Docket Import CDC Prosecuting, Compositions, DA4BXX, DA4XXX, DAXXXX, DC5BXX, DC5XXX, DCXXXX, DETECTING, DEXXXX, DXXXXX, IMMUNOCONTRACEPTIVE, Methods, OID-NCEZID-DHCPP, OID-NCIRD-DVD, PARECHOVIRUS, rabies, recombinant, VIRUS-BASED
Category(s): Collaboration Sought > Licensing, TherapeuticArea > Infectious Disease, Application > Vaccines, Application > Diagnostics
Human DNA Polymerase Gamma for Testing the Effect of Drugs on Mitochondrial Function
One of the primary means for treating HIV infection is the use of antiviral nucleotide or nucleoside analogs. These analogs work by inhibiting the activity of reverse transcriptase, the enzyme responsible for preparing the HIV genome for integration into the DNA of the host cell. Although these analogs do not have an effect on the polymerases responsible...
Published: 10/28/2024   |   Inventor(s): Rajesh Kasiviswanathan, Susan Lim, William Copeland
Keywords(s): CLONE, DDXXXX, DEFICIENT, Directed, DNA, DXXXXX, Enzyme, EXONUCLEASE, Expression, Gamma, Human, Improved, Includes, Listed LPM Campbell as of 4/15/2015, Method, Modifications, polymerase, Polymerase., Post LPM Assignment Set 20150420, Pre LPM working set 20150418, purification, recombinant, RXXXXX, SITE, TYPE, VLXXXX, Which, Wild, WIXXXX, XEXXXX, YBXXXX
Category(s): Collaboration Sought > Collaboration, Application > Research Materials, TherapeuticArea > Infectious Disease, Application > Therapeutics
Cytochromes P450 CYP2J and CYP2C Polyclonal Antibodies and Recombinant Proteins
The National Institutes of Health announces polyclonal antibodies against mouse cytochrome P450s CYP2J and CYP2C. Cytochrome P450s catalyze the metabolism of a wide range of exogenous compounds, including drugs, industrial chemicals, environmental pollutants, and carcinogens. The 2C family of cytochrome P450 metabolizes an extensive number of drugs...
Published: 10/28/2024   |   Inventor(s): Darryl Zeldin
Keywords(s): antibodies, CYP2C, CYP2J, CYTOCHROMES, IDXXXX, IXXXXX, P450, polyclonal, proteins, recombinant
Category(s): Collaboration Sought > Collaboration, Application > Therapeutics, Application > Research Materials, Application > Diagnostics
Biological/Research Material for HIV Vaccine Research
Offered for licensing is a recombinant attenuated vaccinia virus, MVA, that expresses SIV 239gagpol. The materials can be used for research purposes and in particular in the area of HIV/AIDS vaccines. Plasmid insertion vector pJH-4, containing the foreign gene SIV 239 GagPol controlled by vaccinia early/late promoter, inserts into del III of attenuated...
Published: 10/28/2024   |   Inventor(s): Linda Wyatt, Bernard Moss
Keywords(s): 239gagpol, ACXXXX, AXXXXX, DC5XXX, DCXXXX, DXXXXX, EXPRESSES, Gene, MVA/SIV239gagpol, MVNSIV239gagpoi, PJH4, recombinant, RESEARCH MATERIAL, SIV, SIV239gagpol, That, virus
Category(s): Collaboration Sought > Licensing, TherapeuticArea > Infectious Disease, Application > Vaccines
Antigenic Chimeric Tick-Borne Encephalitis Virus/Dengue Virus Type 4 Recombinant Viruses
The tick-borne encephalitis virus (TBEV) complex is a group of viruses that can cause severe neutrotropic disease and up to thirty percent (30%) mortality. While these viruses can be found in many parts of the world, the largest impact of the disease occurs in Europe and Russia, where approximately fourteen thousand (14,000) hospitalized TBEV cases...
Published: 10/28/2024   |   Inventor(s): Brian Murphy, Amber Engel, Alexander Pletnev
Keywords(s): 4, ANTIGENIC, CANDIDATES, CAUSED, chimeric, Chromosome 7, monosomy, DA4BXX, DA4XXX, DAXXXX, DC5BXX, DC5XXX, DCXXXX, DDXXXX, Deletion 7, Dengue (Flaviviridae), Development, Disease, DXXXXX, ENCEPHALITIS, Patent Category - Biotechnology, Prevention, recombinant, TBEV, TBEV/DEN4, TICK-BORNE, Tick-borne encephalitis, TYPE, Vaccine, virus, Virus/dengue, Viruses
Category(s): Collaboration Sought > Collaboration, Application > Research Materials, Application > Diagnostics, Application > Vaccines, TherapeuticArea > Infectious Disease
Recombinant Vaccines Based on Poxvirus Vectors
The technology offered for licensing is foundational in the area of recombinant DNA vaccines. In the last several years, facilitated through a licensing program of the NIH, the technology has been broadly applied in the development and commercialization of several novel human and veterinary vaccines in the areas of infectious disease as well as cancer...
Published: 10/28/2024   |   Inventor(s): Bernard Moss
Keywords(s): B, BBXXXX, BCXXXX, DC5BXX, DC5XXX, DCXXXX, Duke DNA Project, Hepatitis, INFLUENZA, POX VIRUS, rabies, recombinant, vaccines, vaccinia, virus, VLXXXX, VOXXXX, WNXXXX, XKXXXX
Category(s): Collaboration Sought > Licensing, Application > Vaccines, Application > Consumer Products, TherapeuticArea > Infectious Disease
1 2